NZ538958A - Treating disorders of the retina by increasing the in vivo concentration of endostatin in ocular tissues - Google Patents

Treating disorders of the retina by increasing the in vivo concentration of endostatin in ocular tissues

Info

Publication number
NZ538958A
NZ538958A NZ538958A NZ53895803A NZ538958A NZ 538958 A NZ538958 A NZ 538958A NZ 538958 A NZ538958 A NZ 538958A NZ 53895803 A NZ53895803 A NZ 53895803A NZ 538958 A NZ538958 A NZ 538958A
Authority
NZ
New Zealand
Prior art keywords
leu
ser
endostatin
ala
gly
Prior art date
Application number
NZ538958A
Other languages
English (en)
Inventor
Peter Anthony Campochiaro
Michael Kaleko
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31978303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ538958(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ538958A publication Critical patent/NZ538958A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
NZ538958A 2002-08-28 2003-08-27 Treating disorders of the retina by increasing the in vivo concentration of endostatin in ocular tissues NZ538958A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40647002P 2002-08-28 2002-08-28
PCT/EP2003/009497 WO2004020469A2 (en) 2002-08-28 2003-08-27 Ocular gene therapy

Publications (1)

Publication Number Publication Date
NZ538958A true NZ538958A (en) 2006-09-29

Family

ID=31978303

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ538958A NZ538958A (en) 2002-08-28 2003-08-27 Treating disorders of the retina by increasing the in vivo concentration of endostatin in ocular tissues

Country Status (11)

Country Link
US (1) US20070104684A1 (cg-RX-API-DMAC10.html)
EP (1) EP1534751B1 (cg-RX-API-DMAC10.html)
JP (1) JP4612417B2 (cg-RX-API-DMAC10.html)
CN (2) CN100526332C (cg-RX-API-DMAC10.html)
AT (1) ATE464321T1 (cg-RX-API-DMAC10.html)
AU (1) AU2003258675B2 (cg-RX-API-DMAC10.html)
CA (1) CA2496820A1 (cg-RX-API-DMAC10.html)
DE (1) DE60332122D1 (cg-RX-API-DMAC10.html)
IL (1) IL166950A (cg-RX-API-DMAC10.html)
NZ (1) NZ538958A (cg-RX-API-DMAC10.html)
WO (1) WO2004020469A2 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100475270C (zh) * 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174861B1 (en) 1996-10-22 2001-01-16 The Children's Medical Center Corporation Methods of inhibiting angiogenesis via increasing in vivo concentrations of endostatin protein
ATE298371T1 (de) * 1997-09-24 2005-07-15 Univ California Nicht-primaten lentivirale vektoren und verpackungssysteme
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
US6670321B1 (en) * 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
AU2001295193A1 (en) * 2000-05-01 2001-11-12 Novartis Ag Vectors for ocular transduction and use thereof for genetic therapy
AU2001272932A1 (en) * 2000-06-02 2001-12-17 Entremed, Inc Angiostatin and endostatin binding proteins and methods of use
US20020086007A1 (en) * 2000-10-13 2002-07-04 Sim Kim Lee Angiogenesis-inhibiting peptides and proteins and methods of use
EP1401480B1 (en) * 2001-02-22 2012-11-28 Novartis AG Viral vectors encoding endostatin in the treatment of ocular neovascularization
WO2003066810A2 (en) * 2002-02-04 2003-08-14 Novartis Ag Recombinant bovine immunodeficiency virus based gene transfer system
CA2480809A1 (en) * 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
US20060251621A1 (en) * 2002-09-27 2006-11-09 Campochiaro Peter A Ocular gene therapy

Also Published As

Publication number Publication date
EP1534751B1 (en) 2010-04-14
ATE464321T1 (de) 2010-04-15
HK1077306A1 (en) 2006-02-10
EP1534751A2 (en) 2005-06-01
CN101637611A (zh) 2010-02-03
JP2006516112A (ja) 2006-06-22
JP4612417B2 (ja) 2011-01-12
WO2004020469A2 (en) 2004-03-11
DE60332122D1 (de) 2010-05-27
IL166950A (en) 2011-04-28
WO2004020469A3 (en) 2004-04-29
CN1708513A (zh) 2005-12-14
AU2003258675B2 (en) 2009-03-26
US20070104684A1 (en) 2007-05-10
CA2496820A1 (en) 2004-03-11
AU2003258675A1 (en) 2004-03-19
CN100526332C (zh) 2009-08-12

Similar Documents

Publication Publication Date Title
US8338384B2 (en) Method for treating ocular neovascularization
US7989426B2 (en) Selective induction of apoptosis to treat ocular disease by expression of PEDF
AU2004245175B2 (en) Improved secretion of neublastin
US20070098692A1 (en) Materials and methods for treating ocular-related disorders
JP2002502608A (ja) 血管新生促進因子である血管内皮細胞成長因子：ｖｅｇｆの変異体
WO2002026827A1 (en) Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules
US20060251621A1 (en) Ocular gene therapy
AU780634C (en) Gene Therapy for treating ocular-related disorders
Dejneka et al. Gene Therapy and Animal Models for
JP2006518741A (ja) ａｔｏｎａｌ関連因子をコードするベクターを投与することによる耳疾患を治療するための遺伝子治療法
AU2003258675B2 (en) Ocular gene therapy
HK1077306B (en) Ocular gene therapy
JP2022119955A (ja) 血管新生阻害剤としてのｃ型レクチンであるレベセチン
Ribeaudeau et al. In vivo adenovirus-mediated gene transfer to newborn rat retinal pigment epithelial cells
COTLIER et al. Gene Therapy for Genetic and Acquired Retinal Diseases
Stephens Development of gene therapy for the treatment of inherited retinal degeneration
Tombran-Tink New Experimental Therapeutic Approaches for Degenerative Diseases of the Retina
AU2005202935A1 (en) Gene therapy for treating ocular-related disorders
JP2006516112A5 (cg-RX-API-DMAC10.html)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 AUG 2016 BY COMPUTER PACKAGES INC

Effective date: 20140128

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 AUG 2017 BY COMPUTER PACKAGES INC

Effective date: 20160802

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 AUG 2018 BY COMPUTER PACKAGES INC

Effective date: 20180131

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 AUG 2019 BY COMPUTER PACKAGES INC

Effective date: 20180731

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 AUG 2020 BY COMPUTER PACKAGES INC

Effective date: 20190731

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 AUG 2021 BY COMPUTER PACKAGES INC

Effective date: 20200731

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 AUG 2022 BY COMPUTER PACKAGES INC

Effective date: 20210830

LAPS Patent lapsed